+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Insulinoma Treatment - Global Strategic Business Report

  • PDF Icon

    Report

  • 250 Pages
  • June 2025
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5987585
Description Jump to:
The global market for Insulinoma Treatment was estimated at US$3.1 Billion in 2024 and is projected to reach US$3.5 Billion by 2030, growing at a CAGR of 2.5% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Insulinoma Treatment market.

Global Insulinoma Treatment Market - Key Trends and Drivers Summarized

Insulinoma is a rare pancreatic neuroendocrine tumor that results in the overproduction of insulin, leading to hypoglycemia. These tumors are typically benign, but their ability to cause severe hypoglycemia necessitates prompt diagnosis and treatment. Insulinomas are often small and difficult to detect with conventional imaging techniques, making diagnosis challenging. The primary treatment for insulinoma is surgical removal, which is considered curative in most cases. Surgical options include enucleation, where the tumor is removed without taking out a significant portion of the pancreas, and partial pancreatectomy for larger or more diffuse tumors. In cases where surgery is not feasible, medical management with drugs like diazoxide or somatostatin analogs can help control hypoglycemia. Advanced imaging techniques, such as endoscopic ultrasound and intraoperative ultrasound, are increasingly utilized to improve the accuracy of tumor localization.

Recent advancements in the treatment of insulinoma focus on enhancing surgical outcomes and exploring non-surgical options. Minimally invasive surgical techniques, such as laparoscopic and robotic-assisted surgery, have become more prevalent, offering patients reduced recovery times and fewer complications compared to traditional open surgery. Additionally, research into ablative techniques, including radiofrequency ablation and microwave ablation, is ongoing, providing potential non-surgical alternatives for treating insulinomas. On the medical management front, newer somatostatin analogs and targeted therapies are under investigation, aiming to provide more effective control of insulin secretion and hypoglycemia. Moreover, advancements in molecular imaging, such as PET scans using radiolabeled octreotide, are improving the detection and characterization of these tumors, facilitating more precise treatment planning.

The growth in the insulinoma treatment market is driven by several factors. Technological advancements in imaging and surgical techniques are expanding the range of effective treatment options available, improving patient outcomes. The increasing prevalence of diabetes and related metabolic disorders is leading to heightened awareness and more frequent screening for insulinoma, thereby driving demand for diagnostic and therapeutic solutions. Significant investments in research and development by pharmaceutical and medical device companies are accelerating the introduction of innovative treatments and technologies. Regulatory support, including approvals for new diagnostic tools and therapeutic agents, is facilitating quicker access to advanced treatment options. Additionally, the rising adoption of minimally invasive surgical techniques is generating demand for specialized surgical instruments and expertise. Public health initiatives and patient advocacy efforts are also playing a crucial role in raising awareness about insulinoma, promoting early diagnosis and treatment, and supporting the overall growth of the market.

SCOPE OF STUDY:

The report analyzes the Insulinoma Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:
  • Segments: Treatment Type (Surgery, Drugs, Other Treatment Types); Type (Benign, Metastasize)
  • Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Surgery segment, which is expected to reach US$2.1 Billion by 2030 with a CAGR of a 2.1%. The Drugs segment is also set to grow at 2.9% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, valued at $829.9 Million in 2024, and China, forecasted to grow at an impressive 4.3% CAGR to reach $674.4 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Insulinoma Treatment Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Insulinoma Treatment Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Insulinoma Treatment Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of players such as Eiger BioPharmaceuticals, Inc., Exelixis, Inc., HUTCHMED, Ipsen Pharma, Isotopen Technologien Munchen and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 86 companies featured in this Insulinoma Treatment market report include:

  • Eiger BioPharmaceuticals, Inc.
  • Exelixis, Inc.
  • HUTCHMED
  • Ipsen Pharma
  • Isotopen Technologien Munchen
  • Novartis AG
  • Oncolytics Biotech Inc.
  • Pfizer, Inc.
  • Rezolute
  • Xeris Biopharma Holdings, Inc.

This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:

  • Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
  • Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015.
  • Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
  • Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
  • Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
  • Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
  • Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
Global Economic Update
Insulinoma Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Advancements in Imaging Technologies Propel Growth in Insulinoma Treatment Market
Minimally Invasive Surgical Techniques Expand Addressable Market Opportunity for Insulinoma Treatments
Innovative Ablative Techniques Strengthen Business Case for Non-Surgical Insulinoma Therapies
Emerging Targeted Therapies Spur Demand for Advanced Insulinoma Treatments
Increased Awareness and Screening for Metabolic Disorders Drive Adoption of Insulinoma Diagnostic Solutions
Technological Advancements in Molecular Imaging Enhance Precision in Insulinoma Treatment Planning
Focus on Reducing Surgical Complications Enhances Demand for Advanced Insulinoma Treatment Techniques
Advancements in Endoscopic and Intraoperative Ultrasound Sustain Growth in Insulinoma Treatment Market
Increasing Prevalence of Diabetes and Related Conditions Spurs Growth in Insulinoma Diagnostics and Treatments
Development of New Somatostatin Analogs Drives Adoption of Medical Management Options for Insulinoma
Growing Use of PET Scans in Insulinoma Diagnosis Expands Addressable Market for Imaging Solutions
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Insulinoma Treatment Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Insulinoma Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 3: World Historic Review for Insulinoma Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 4: World 15-Year Perspective for Insulinoma Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 6: World Historic Review for Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 7: World 15-Year Perspective for Surgery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 9: World Historic Review for Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 10: World 15-Year Perspective for Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 12: World Historic Review for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 13: World 15-Year Perspective for Other Treatment Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Benign by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 15: World Historic Review for Benign by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 16: World 15-Year Perspective for Benign by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Metastasize by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 18: World Historic Review for Metastasize by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 19: World 15-Year Perspective for Metastasize by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
Insulinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
TABLE 20: USA Recent Past, Current & Future Analysis for Insulinoma Treatment by Treatment Type - Surgery, Drugs and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 21: USA Historic Review for Insulinoma Treatment by Treatment Type - Surgery, Drugs and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 22: USA 15-Year Perspective for Insulinoma Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Drugs and Other Treatment Types for the Years 2015, 2025 & 2030
TABLE 23: USA Recent Past, Current & Future Analysis for Insulinoma Treatment by Type - Benign and Metastasize - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 24: USA Historic Review for Insulinoma Treatment by Type - Benign and Metastasize Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 25: USA 15-Year Perspective for Insulinoma Treatment by Type - Percentage Breakdown of Value Sales for Benign and Metastasize for the Years 2015, 2025 & 2030
CANADA
TABLE 26: Canada Recent Past, Current & Future Analysis for Insulinoma Treatment by Treatment Type - Surgery, Drugs and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 27: Canada Historic Review for Insulinoma Treatment by Treatment Type - Surgery, Drugs and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 28: Canada 15-Year Perspective for Insulinoma Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Drugs and Other Treatment Types for the Years 2015, 2025 & 2030
TABLE 29: Canada Recent Past, Current & Future Analysis for Insulinoma Treatment by Type - Benign and Metastasize - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 30: Canada Historic Review for Insulinoma Treatment by Type - Benign and Metastasize Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 31: Canada 15-Year Perspective for Insulinoma Treatment by Type - Percentage Breakdown of Value Sales for Benign and Metastasize for the Years 2015, 2025 & 2030
JAPAN
Insulinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
TABLE 32: Japan Recent Past, Current & Future Analysis for Insulinoma Treatment by Treatment Type - Surgery, Drugs and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 33: Japan Historic Review for Insulinoma Treatment by Treatment Type - Surgery, Drugs and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 34: Japan 15-Year Perspective for Insulinoma Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Drugs and Other Treatment Types for the Years 2015, 2025 & 2030
TABLE 35: Japan Recent Past, Current & Future Analysis for Insulinoma Treatment by Type - Benign and Metastasize - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 36: Japan Historic Review for Insulinoma Treatment by Type - Benign and Metastasize Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 37: Japan 15-Year Perspective for Insulinoma Treatment by Type - Percentage Breakdown of Value Sales for Benign and Metastasize for the Years 2015, 2025 & 2030
CHINA
Insulinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
TABLE 38: China Recent Past, Current & Future Analysis for Insulinoma Treatment by Treatment Type - Surgery, Drugs and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 39: China Historic Review for Insulinoma Treatment by Treatment Type - Surgery, Drugs and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 40: China 15-Year Perspective for Insulinoma Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Drugs and Other Treatment Types for the Years 2015, 2025 & 2030
TABLE 41: China Recent Past, Current & Future Analysis for Insulinoma Treatment by Type - Benign and Metastasize - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 42: China Historic Review for Insulinoma Treatment by Type - Benign and Metastasize Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 43: China 15-Year Perspective for Insulinoma Treatment by Type - Percentage Breakdown of Value Sales for Benign and Metastasize for the Years 2015, 2025 & 2030
EUROPE
Insulinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
TABLE 44: Europe Recent Past, Current & Future Analysis for Insulinoma Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 45: Europe Historic Review for Insulinoma Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 46: Europe 15-Year Perspective for Insulinoma Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
TABLE 47: Europe Recent Past, Current & Future Analysis for Insulinoma Treatment by Treatment Type - Surgery, Drugs and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 48: Europe Historic Review for Insulinoma Treatment by Treatment Type - Surgery, Drugs and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 49: Europe 15-Year Perspective for Insulinoma Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Drugs and Other Treatment Types for the Years 2015, 2025 & 2030
TABLE 50: Europe Recent Past, Current & Future Analysis for Insulinoma Treatment by Type - Benign and Metastasize - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 51: Europe Historic Review for Insulinoma Treatment by Type - Benign and Metastasize Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 52: Europe 15-Year Perspective for Insulinoma Treatment by Type - Percentage Breakdown of Value Sales for Benign and Metastasize for the Years 2015, 2025 & 2030
FRANCE
Insulinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
TABLE 53: France Recent Past, Current & Future Analysis for Insulinoma Treatment by Treatment Type - Surgery, Drugs and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 54: France Historic Review for Insulinoma Treatment by Treatment Type - Surgery, Drugs and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 55: France 15-Year Perspective for Insulinoma Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Drugs and Other Treatment Types for the Years 2015, 2025 & 2030
TABLE 56: France Recent Past, Current & Future Analysis for Insulinoma Treatment by Type - Benign and Metastasize - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 57: France Historic Review for Insulinoma Treatment by Type - Benign and Metastasize Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 58: France 15-Year Perspective for Insulinoma Treatment by Type - Percentage Breakdown of Value Sales for Benign and Metastasize for the Years 2015, 2025 & 2030
GERMANY
Insulinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
TABLE 59: Germany Recent Past, Current & Future Analysis for Insulinoma Treatment by Treatment Type - Surgery, Drugs and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 60: Germany Historic Review for Insulinoma Treatment by Treatment Type - Surgery, Drugs and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 61: Germany 15-Year Perspective for Insulinoma Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Drugs and Other Treatment Types for the Years 2015, 2025 & 2030
TABLE 62: Germany Recent Past, Current & Future Analysis for Insulinoma Treatment by Type - Benign and Metastasize - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 63: Germany Historic Review for Insulinoma Treatment by Type - Benign and Metastasize Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 64: Germany 15-Year Perspective for Insulinoma Treatment by Type - Percentage Breakdown of Value Sales for Benign and Metastasize for the Years 2015, 2025 & 2030
ITALY
TABLE 65: Italy Recent Past, Current & Future Analysis for Insulinoma Treatment by Treatment Type - Surgery, Drugs and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 66: Italy Historic Review for Insulinoma Treatment by Treatment Type - Surgery, Drugs and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 67: Italy 15-Year Perspective for Insulinoma Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Drugs and Other Treatment Types for the Years 2015, 2025 & 2030
TABLE 68: Italy Recent Past, Current & Future Analysis for Insulinoma Treatment by Type - Benign and Metastasize - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 69: Italy Historic Review for Insulinoma Treatment by Type - Benign and Metastasize Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 70: Italy 15-Year Perspective for Insulinoma Treatment by Type - Percentage Breakdown of Value Sales for Benign and Metastasize for the Years 2015, 2025 & 2030
UNITED KINGDOM
Insulinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
TABLE 71: UK Recent Past, Current & Future Analysis for Insulinoma Treatment by Treatment Type - Surgery, Drugs and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 72: UK Historic Review for Insulinoma Treatment by Treatment Type - Surgery, Drugs and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 73: UK 15-Year Perspective for Insulinoma Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Drugs and Other Treatment Types for the Years 2015, 2025 & 2030
TABLE 74: UK Recent Past, Current & Future Analysis for Insulinoma Treatment by Type - Benign and Metastasize - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 75: UK Historic Review for Insulinoma Treatment by Type - Benign and Metastasize Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 76: UK 15-Year Perspective for Insulinoma Treatment by Type - Percentage Breakdown of Value Sales for Benign and Metastasize for the Years 2015, 2025 & 2030
SPAIN
TABLE 77: Spain Recent Past, Current & Future Analysis for Insulinoma Treatment by Treatment Type - Surgery, Drugs and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 78: Spain Historic Review for Insulinoma Treatment by Treatment Type - Surgery, Drugs and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 79: Spain 15-Year Perspective for Insulinoma Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Drugs and Other Treatment Types for the Years 2015, 2025 & 2030
TABLE 80: Spain Recent Past, Current & Future Analysis for Insulinoma Treatment by Type - Benign and Metastasize - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 81: Spain Historic Review for Insulinoma Treatment by Type - Benign and Metastasize Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 82: Spain 15-Year Perspective for Insulinoma Treatment by Type - Percentage Breakdown of Value Sales for Benign and Metastasize for the Years 2015, 2025 & 2030
RUSSIA
TABLE 83: Russia Recent Past, Current & Future Analysis for Insulinoma Treatment by Treatment Type - Surgery, Drugs and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 84: Russia Historic Review for Insulinoma Treatment by Treatment Type - Surgery, Drugs and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 85: Russia 15-Year Perspective for Insulinoma Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Drugs and Other Treatment Types for the Years 2015, 2025 & 2030
TABLE 86: Russia Recent Past, Current & Future Analysis for Insulinoma Treatment by Type - Benign and Metastasize - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 87: Russia Historic Review for Insulinoma Treatment by Type - Benign and Metastasize Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 88: Russia 15-Year Perspective for Insulinoma Treatment by Type - Percentage Breakdown of Value Sales for Benign and Metastasize for the Years 2015, 2025 & 2030
REST OF EUROPE
TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Insulinoma Treatment by Treatment Type - Surgery, Drugs and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 90: Rest of Europe Historic Review for Insulinoma Treatment by Treatment Type - Surgery, Drugs and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 91: Rest of Europe 15-Year Perspective for Insulinoma Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Drugs and Other Treatment Types for the Years 2015, 2025 & 2030
TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Insulinoma Treatment by Type - Benign and Metastasize - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 93: Rest of Europe Historic Review for Insulinoma Treatment by Type - Benign and Metastasize Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 94: Rest of Europe 15-Year Perspective for Insulinoma Treatment by Type - Percentage Breakdown of Value Sales for Benign and Metastasize for the Years 2015, 2025 & 2030
ASIA-PACIFIC
Insulinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Insulinoma Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 96: Asia-Pacific Historic Review for Insulinoma Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 97: Asia-Pacific 15-Year Perspective for Insulinoma Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Insulinoma Treatment by Treatment Type - Surgery, Drugs and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 99: Asia-Pacific Historic Review for Insulinoma Treatment by Treatment Type - Surgery, Drugs and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 100: Asia-Pacific 15-Year Perspective for Insulinoma Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Drugs and Other Treatment Types for the Years 2015, 2025 & 2030
TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Insulinoma Treatment by Type - Benign and Metastasize - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 102: Asia-Pacific Historic Review for Insulinoma Treatment by Type - Benign and Metastasize Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 103: Asia-Pacific 15-Year Perspective for Insulinoma Treatment by Type - Percentage Breakdown of Value Sales for Benign and Metastasize for the Years 2015, 2025 & 2030
AUSTRALIA
Insulinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
INDIA
Insulinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
SOUTH KOREA
REST OF ASIA-PACIFIC
LATIN AMERICA
Insulinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
ARGENTINA
BRAZIL
MEXICO
REST OF LATIN AMERICA
MIDDLE EAST
Insulinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
IRAN
ISRAEL
SAUDI ARABIA
UNITED ARAB EMIRATES
REST OF MIDDLE EAST
AFRICA
Insulinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Eiger BioPharmaceuticals, Inc.
  • Exelixis, Inc.
  • HUTCHMED
  • Ipsen Pharma
  • Isotopen Technologien Munchen
  • Novartis AG
  • Oncolytics Biotech Inc.
  • Pfizer, Inc.
  • Rezolute
  • Xeris Biopharma Holdings, Inc.

Table Information

Report AttributeDetails
No. of Pages250
PublishedJune 2025
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 3.1 Billion
Forecasted Market Value ( USD ) by 2030 $ 3.5 Billion
Compound Annual Growth Rate2.5%
Regions CoveredGlobal

Related Topics

Related Reports

Insulinoma Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Insulinoma Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 86 Pages
  • Global
From
Metastatic Bone Disease - Global Strategic Business Report - Product Image

Metastatic Bone Disease - Global Strategic Business Report

  • Report
  • 194 Pages
  • Global
From
Desmoid Tumors Market Report 2025 - Product Image

Desmoid Tumors Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Anaplastic Thyroid Cancer Drugs - Global Strategic Business Report - Product Image

Anaplastic Thyroid Cancer Drugs - Global Strategic Business Report

  • Report
  • 142 Pages
  • Global
From
Medullary Thyroid Cancer - Pipeline Insight, 2025 - Product Image

Medullary Thyroid Cancer - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From

About the Islet Cell Carcinoma Drug Market

Islet Cell Carcinoma (ICC) is a rare form of cancer that affects the islet cells of the pancreas. It is a type of neuroendocrine tumor, which is a type of cancer that develops from cells that release hormones into the bloodstream. Treatment for ICC typically involves a combination of surgery, chemotherapy, and radiation therapy. Oncology drugs are used to treat cancer, including ICC. These drugs can be used to reduce the size of tumors, slow the growth of cancer cells, and reduce the side effects of other treatments. Commonly used oncology drugs for ICC include somatostatin analogs, interferon-alpha, and chemotherapy drugs. The Islet Cell Carcinoma Drug market is a rapidly growing segment of the oncology drug market. As the incidence of ICC increases, the demand for effective treatments is also increasing. Companies in this market include Novartis, Pfizer, and Merck. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.